Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My bad you are right, they are just changing the parameters to enroll faster is all. Still it is not a huge delay that many are making it out to be.
I don't see management selling for that low given the potential? Plus Broadfin is a larger shareholder. Wouldn't a larger portion of sharehodlers have to approve the deal in order for that to go through? I don't think Broadfin would allow for such a transaction.
That would be a nice premium. As $200 mil for the companies tech is doable value considering the scar program and cosmecueticals program. But who knows?
$200 mil buyout would equate to around $20 per share
What share price would $200 mil buyout be?
But if it is that would mean J&J is buying it out. But at what price would be reasonable for a buyout of a company that should be worth between $500 mil and 1 billion?
The panic happened because the company had to submit a new protocol for the adjunct therapy since patient enrollment wasn't happening fast enough. Although, I don't agree that the price should have fallen because of that. IMO faster recruitment = better for timeframe of trial to finish. Sure it is delayed slightly by a few months but it shouldn't be cause for concerned as long as PRO 140 makes it to the finish line.
That won't make it that high, because as I have been stating. Gilead Sciences makes 44% of its yearly revenue on its HIV treatment. If Cytodyn comes to market it will take all that market share away. Does anyone honestly believe that Gilead SCiences will hang back and do nothing while a small biotech company gets a drug FDA approved and becomes the new SOC? I Don't think so.
It will get bought out way before them IMO. Bank on it, and mark this post for when it happens.
Or you could just long CYDY for when Gilead makes its bid on the company. Because Gilead is probably watching this closely and it doesn't want to lose 44% of its yearly revenue.
Big volume today but I'm still bullish on the June 20th conference for phase 2b monotherapy results. Will add on dips even afterwards, the main goal is for PRO 140 to get to market. Will it take longer? Quite possibly, but the key is that it will hit the market pending FDA approves and that's all that matters. stick this in your retirement account
Thanks for the video, so it should be a good idea to keep an eye on the .95 cent level as support. If that can hold and bounce would be a good idea to add. If not it will probably head lower. I will add shares in the coming weeks again anyways.
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments
http://finance.yahoo.com/news/rxi-pharmaceuticals-reports-first-quarter-110200113.html
Not only that patients have to go to the hospital twice a month for an IV. Therefore ibalizumab won't be as competitive as PRO 140
Yah no reverse split mentioned. So that's a huge plus
RXi Pharmaceuticals Provides Strategic Update
http://finance.yahoo.com/news/rxi-pharmaceuticals-provides-strategic-105500037.html
RXII a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced that it is in the process of exploring strategic options including a range of potential M&A and business development opportunities designed to enhance shareholder value. As part of this effort, RXi has engaged Griffin Securities, Inc. ("Griffin") for one of these transactions.
What's the catch for Gilead Sciences trading at around $1 back in 1999? There is no catch, the catch is investors don't catch onto something good early on. that's the catch.
Go to google finance and look at the chart for "ALL"
https://www.google.com/finance?q=gilead+sciences&ei=yYIvV9nNIsKce_m6i6gG
from 1992 to 1999 share price for GILD was at 1.07 per share on average. It didn't take off until 2001 to 2002. never look at a current stock price to determine future performance not how the stock market works. Gotta look at the bigger picture.
In addition Priceline traded at $5 per share back in 2000, today PCLN trades at $1,133 per share.
Regeneron traded at $5 per share back in 2009, today it trades around $369 per share.
There is no guarantee in biotech however, but never judge a stock based on its current trading performance.
Well its logical sense competition has to be kept in check. For instance Regeneron garnered a partnership deal with Avalanche biotech before the bad phase 2 data for macular degeneration. Regeneron partnered with it way before phase 2 had even started. But Regeneron did so because if Avalanche was successful with gene therapy it would have taken away from Elyea sales in the macular degeneration space.
It's common sense these big pharma companies defend the big positions they are in. In the case of Gilead it will defend itself vigorously not to lose its HIV profit. -- 44% of yearly revenue.
I know I'm beating a dead horse here, but you are right. If the data is good Gilead stands to lose its 44% yearly revenue in the HIV space. After the blow it took from lower Hep C sales, and a falling share price along with $28 billion in the bank, I don't see why they wouldn't attempt to buy CYDY out.
The big date is June 20th. Because if the data is as good as we think and hope it is, then Gilead Sciences is gonna buy out CYDY. If it wants to protect its 44% HIV revenue it will have no other choice. To Da Moon Baby!
I wish I knew, man. maybe pure manipulation? Who knows?
its up tonight look on yahoo. 8-k filed Rxi regained compliance
I think that the PR didn't have the effect that it did because the FDA approves 99.5% of all compassionate use submissions. Therefore it was already known.
Thera will pay for all costs of the trials, and Rxi provides its SOD1 RNAi compound.
Hopefully higher, but I would like to add more CYDY shares. Also the RXII I'm in got ALS partnership news.
partnership newss http://finance.yahoo.com/news/cytodyn-compassionate-protocol-receives-fda-100000147.html
TheraNeuropro will pay for all costs of trials etc. will use Rxi's ALS compound.
Very nice news! The patient can continue on the therapy as he likes, and it's good to see the FDA give the clearance. I really wanted to add more we shall see how high this news takes us. But I will continue to add shares!
CytoDyn’s Compassionate Use Protocol Receives FDA Clearance to Proceed
http://globenewswire.com/news-release/2016/05/03/835873/0/en/CytoDyn-s-Compassionate-Use-Protocol-Receives-FDA-Clearance-to-Proceed.html
CYDY is holding well at this level. I have seen it bounce from $1.17 multiple times now as support. Seems there is a lot of buying below $1.19 area. Should keep it propped up at that level until we get more news.
ARVO poster is up here is the link:
http://investors.rxipharma.com/Cache/1500084739.PDF?O=PDF&T=&Y=&D=&FID=1500084739&iid=4418218
Looking real good!
NITE and CANT can't be too happy about their losses they are the number 1's in short selling on the OTC. I'm sure they gonna be covering more shortly with good news coming down the pipe.
Nice find, I like the prospects of Pro 140 so much.
Yes that's what I saw in the video they have right now weekly injections, but it may be possible to do once a month injection with more testing. If they can get monotherapy to one time a month treatment for HIV that will be golden. Heck once a week is already golden, taking it to once a month is like icing on the cake.
Which post do you need stickied? I don't see a 1973
JP company doesn't care, as long as Gerald and his father are getting a 200k to 300k yearly paycheck why should they? That's their mentality. If they truly cared about creating shareholder value they would have advanced Lympro into CLIA, and advanced MANF into the clinic.
Had management stuck to the original plan of getting CLIA for Lympro, and sticking with Eltoprazine, and MANF keeping pipeline small would have been good. With no money, why branch out to terrible stuff like MSprecise, ESS. Just keep pipeline small since the company doesn't have a lot of money. The CEO is totally clueless.
nice find the Adjunct therapy with Pro 140 could come as early as 2017.
On that assessment I like that the technology PRO 140 just doesn't go after HIV. Company can go after cancer and autoimmune diseases.
In cancer they are starting with GvHD if that goes well then later on with more money they can branch to other types of cancer.
Think of PRO 140 monoclonal antibody as a platform that can go after multiple targets not just HIV.
yes those PRS were just stating how many months patients were viral free. This will be in depth data on viral loads and more in depth. They have not yet released detailed data, until the June 20th conference.
You are correct, and to top it off that data to be revealed on June 20th is for the phase 2b monotherapy data. That is important because if the monotherapy data is that great, then the adjuvant therapy is even better.
But the Monotherapy will be king as it proves that PRO 140 monocolonal antibodies can stand alone and fend off HIV cells from infecting T-cells. If that's the case I see Gilead Sciences offering $2 bil to $5 bil for a buyout.